Serum Peak Sulfamethoxazole Concentrations Demonstrate Difficulty in Achieving a Target Range: A Retrospective Cohort Study

Current Therapeutic Research - Clinical and Experimental

Volumn 76, Issue , 2014, Pages 104-109

  Dao, Bao D ^a,b   Barreto, Jason N ^a   Wolf, Robert C ^a   Dierkhising, Ross A ^a   Plevak, Matthew F ^a   Tosh, Pritish K ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Serum peak concentration; Sulfamethoxazole; Therapeutic drug monitoring; Trimethoprim

Indexed keywords

COTRIMOXAZOLE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG MONITORING; FEMALE; HOSPITAL PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; YOUNG ADULT;

EID: 84909965607     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2014.08.003     Document Type: Article

References (28)

1. Vohringer H.F., Arasteh K. Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. Clin Pharmacokinet 1993, 24:388-412.
2. Limper A.H., Knox K.S., Sarosi G.A., et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011, 183:96-128.
3. Mofenson L.M., Brady M.T., Danner S.P., et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009, 58:1-166.
4. Smego R.A., Moeller M.B., Gallis H.A. Trimethoprim-sulfamethoxazole therapy for Nocardia infections. Arch Intern Med 1983, 143:711-718.
5. Abbott I.J., Slavin M.A., Turnidge J.D., Thursky K.A., Worth L.J. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther 2011, 9:471-488.
6. Blaser J., Joos B., Opravil M., Luthy R. Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. Infection 1993, 21:206-209.
7. Wharton J.M., Coleman D.L., Wofsy C.B., et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1986, 105:629-630.
8. Joos B., Blaser J., Opravil M., Chave J.P., Luthy R. Monitoring of co-trimoxazole concentrations in serum during treatment of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1995, 39:2661-2666.
9. Klinker H., Langmann P., Zilly M., Richter E. Drug monitoring during the treatment of AIDS-associated Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole. J Clin Pharm Ther 1998, 23:149-154.
10. Hughes W.T., Feldman S., Chaudhary S.C., Ossi M.J., Cox F., Sanyal S.K. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr 1978, 92:285-291.
11. Wong IW. Correlation of Side Effects of Trimethoprim/sulfamethoxazole with blood levels in AIDS patients treated for Pneumocystis carinii pneumonia. In: 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC; 1988:328.
12. Bowden F.J., Harman P.J., Lucas C.R. Serum trimethoprim and sulphamethoxazole levels in AIDS. Lancet 1986, 1:853.
13. Kremers P., Duvivier J., Heusghem C. Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses. J Clin Pharmacol 1974, 14:112-117.
14. Sulfamethoxazole, Serum. Mayo Medical Laboratories. Available at: . Accessed August 13, 2013. http://www.mayomedicallaboratories.com/test-catalog/Overview/8238.
15. Wilson J.W., Estes L.L. Mayo Clinic. Mayo Clinic antimicrobial therapy: quick guide 2008, Mayo Clinic Scientific Press, Rochester, MN.
16. Bactrim™ and Bactrim ™ DS (sulfamethoxazole and trimethoprim) [package insert]. Philadelphia PAS, Inc; 2013.
17. Nahata M.C. Dosage regimens of trimethoprim/sulfamethoxazole (TPM/SMX) in patients with renal dysfunction. Ann Pharmacother 1995, 29:1300.
18. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
19. D'Agostino R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17:2265-2281.
20. Lee B.L., Medina I., Benowitz N.L., Jacob P., Wofsy C.B., Mills J.T. Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med 1989, 110:606-611.
21. McLean I., Lucas C.R., Mashford M.L., Harman P.J. Modified trimethoprim-sulphamethoxazole doses in Pneumocystis carinii pneumonia. Lancet 1987, 2:857-858.
22. Medina I., Mills J., Leoung G., et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990, 323:776-782.
23. Moran S.M., Myers B.D. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int 1985, 27:928-937.
24. Perrone R.D., Madias N.E., Levey A.S. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992, 38:1933-1953.
25. Robert S., Zarowitz B.J. Is there a reliable index of glomerular filtration rate in critically ill patients?. DICP: The annals of pharmacotherapy 1991, 25(2):169-178. PMID: 2058189.
26. Clajus C., Kuhn-Velten W.N., Schmidt J.J., et al. Cotrimoxazole plasma levels, dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of under-dosing using current dosing recommendations. BMC Pharmacol Toxicol 2013, 14:19.
27. Curkovic I., Luthi B., Franzen D., Ceschi A., Rudiger A., Corti N. Trimethoprim/sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration. Ann Pharmacother 2010, 44:1669-1672.
28. Chin T.W., Vandenbroucke A., Fong I.W. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother 1995, 39:28-33.